Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PARAMETER: LCZ696 vs Olmesartan in Elderly Hypertension
NCT01692301Phase 2Completed
- Sponsor
- Novartis
- Start
- Dec 2012
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 2, randomised, double-blind trial of sacubitril + valsartan in hypertension (HTN) (2 arms), sponsored by Novartis. Primary endpoint: Central Aortic Systolic Pressure at 12 weeks. Started Dec 2012; status: completed.
02
Drugs
sacubitril + valsartan
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT01692301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01692301.